# Chemo-Sero-Therapeutic Research Institute
**Wikidata**: [Q11400693](https://www.wikidata.org/wiki/Q11400693)  
**Source**: https://4ort.xyz/entity/chemo-sero-therapeutic-research-institute

## Summary
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) is a Japanese research institute and pharmaceutical company founded in 1945, specializing in medical research, vaccine development, and blood-related therapies. Headquartered in Kita-ku, Japan, it operates as a general foundation and is recognized for its dual role in scientific investigation and pharmaceutical production.

## Key Facts
- Founded on December 1, 1945, as a general foundation in Japan.
- Official names: 一般財団法人化学及血清療法研究所 (Japanese) and The Chemo-Sero-Therapeutic Research Institute (English).
- Headquartered in Kita-ku, Japan.
- Known aliases: Kaketsuken, 化血研.
- Legal form: General foundation.
- Corporate Number (Japan): 6330005006672.
- GRID ID: grid.418479.7.
- VIAF ID: 295063425.
- ISNI: 0000000403761390.
- Ringgold ID: 13336 (linked to KM Biologics Kabushiki Kaisha).
- Website: http://www.kaketsuken.or.jp/.
- Industry: Research and pharmaceuticals.
- Wikipedia coverage: 2 language editions (Commons, Japanese).
- Opencorporates ID: jp/6330005006672.
- Google Knowledge Graph ID: /g/121hfvcq.
- Library of Congress Authority ID: n2018063435.

## FAQs
### Q: What is the Chemo-Sero-Therapeutic Research Institute's primary focus?
A: It conducts medical research, develops vaccines, and produces blood-related therapies, operating as both a research institute and a pharmaceutical company.

### Q: When was the institute founded?
A: It was established on December 1, 1945.

### Q: How is it related to KM Biologics?
A: The institute is linked to KM Biologics Kabushiki Kaisha through its Ringgold ID, indicating a corporate affiliation.

### Q: What legal structure does it operate under?
A: It is organized as a general foundation under Japanese law.

### Q: Where is it headquartered?
A: Its headquarters are located in Kita-ku, Japan.

## Why It Matters
The Chemo-Sero-Therapeutic Research Institute plays a critical role in advancing medical science and public health in Japan. As a dual research institute and pharmaceutical company, it bridges fundamental scientific inquiry with practical applications, such as vaccine development and blood therapy production. Its long-standing history since 1945 and affiliation with entities like KM Biologics underscore its enduring impact on Japan’s healthcare infrastructure. By integrating research and manufacturing, the institute contributes to both scientific knowledge and the production of life-saving medical products, addressing societal needs for disease prevention and treatment.

## Notable For
- Operating as both a research institute and a pharmaceutical company, a unique dual role.
- Founded in 1945, reflecting a legacy of scientific contribution in post-war Japan.
- Recognized under multiple international identifiers (GRID, VIAF, ISNI, Ringgold).
- Legal status as a general foundation, distinct from private or governmental entities.
- Affiliation with KM Biologics Kabushiki Kaisha, linking research to commercial pharmaceutical activities.

## Body

### History and Founding
The Chemo-Sero-Therapeutic Research Institute was established on December 1, 1945, as a general foundation in Japan. Its founding marked a significant initiative in post-war Japan to advance medical research and pharmaceutical development. Over time, the institute evolved to incorporate both research and manufacturing functions, solidifying its role in the country’s healthcare ecosystem.

### Organization and Structure
- **Legal Form**: Operates as a general foundation under Japanese law, distinct from private corporations or governmental agencies.
- **Headquarters**: Based in Kita-ku, Japan, with corporate number 6330005006672.
- **Affiliations**: Linked to KM Biologics Kabushiki Kaisha through its Ringgold ID (13336), indicating a strategic partnership or corporate integration.

### Research and Industry Focus
The institute specializes in:
- Medical research, particularly in serotherapy and blood-related treatments.
- Vaccine development and production.
- Pharmaceutical manufacturing, bridging scientific discovery with practical healthcare solutions.

### Identifiers and Recognition
- **GRID ID**: grid.418479.7 (Global Research Identifier Database).
- **VIAF ID**: 295063425 (Virtual International Authority File).
- **ISNI**: 0000000403761390 (International Standard Name Identifier).
- **Opencorporates ID**: jp/6330005006672, verifying its corporate registration in Japan.
- **Wikipedia Coverage**: Featured in 2 language editions (Japanese and Commons), highlighting its national and international relevance.

### Related Entities
- **KM Biologics Kabushiki Kaisha**: Associated through the Ringgold ID, suggesting collaboration or shared corporate structure.
- **Library of Congress Authority ID**: n2018063435, cataloging its contributions to scientific literature.

### Online Presence
- **Official Website**: http://www.kaketsuken.or.jp/.
- **Google Knowledge Graph ID**: /g/121hfvcq, enhancing its digital visibility.

### Legacy and Impact
As a designated foundation, the institute maintains a commitment to public benefit through research and pharmaceutical innovation. Its dual role as a research entity and manufacturer enables direct translation of scientific findings into medical products, addressing critical healthcare challenges in Japan and beyond.

## References

1. GRID Release 2017-01-10